MedTrace Logo

Capecitabine in Women With Operable Breast Cancer

NCT00148720 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2015-11-11

No results posted yet for this study

Summary

The purpose of this study is to find out what effects (good and bad) taking capecitabine for 12 weeks before surgery will have on women with breast cancer.

Conditions

  • Invasive Breast Carcinoma
  • Primary Invasive Breast Cancer
  • Stage I Breast Cancer
  • Stage II Breast Cancer
  • Stage III Breast Cancer

Interventions

DRUG

Capecitabine

Taken orally twice a day for 14 days and treatment will repeat every 21 days (1 cycle) for 4 cycles

Sponsors & Collaborators

Principal Investigators

  • Ian Krop, MD, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2007-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00148720 on ClinicalTrials.gov